De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial

Clark, Richard E, Polydoros, Fotios, Apperley, Jane F · The Lancet Haematology · 2019